User:Mr. Ibrahem/Mometasone

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Mometasone
Clinical data
Trade namesNasonex, Asmanex, Elocon, others[1]
Other namesLAS-41002, 9α,21-Dichloro-11β,17α-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17α-(2-furoate)
AHFS/Drugs.comMain: Monograph
Nose: Monograph
Topical: Monograph
License data
Pregnancy
category
Routes of
administration		Topical, inhalation (nasal spray)
Drug classCorticosteroid; glucocorticoid
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone[3]
Protein binding98% to 99%
MetabolismLiver
Elimination half-life5.8 hours
Identifiers
  • (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
Chemical and physical data
FormulaC22H28Cl2O4 for mometasone
C27H30O6Cl2 as furoate
Molar mass427.361 g/mol (mometasone)
521.4 g/mol (furoate)
3D model (JSmol)
  • CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)O)C)O)Cl)C

  • CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C
  • InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 checkY
  • Key:QLIIKPVHVRXHRI-CXSFZGCWSA-N checkY

  • InChI=1S/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1
  • Key:WOFMFGQZHJDGCX-ZULDAHANSA-N
 ☒NcheckY (what is this?)  (verify)

Mometasone, also known as mometasone furoate, is a steroid medication used to treat certain skin conditions, hay fever, and asthma.[6][7][8] Specifically it is used to prevent rather than treat asthma attacks.[6] It can be applied to the skin, inhaled, or used in the nose.[6][7][8] Mometasone furoate, not mometasone is used in medical products.[9]

Common side effects when used for asthma include headache, sore throat, and thrush.[6] It is therefore recommended to rinse the mouth after use.[6] Long term use may increase the risk for glaucoma and cataracts.[6] Common side effects when used in the nose includes upper respiratory tract infections and nose bleeds.[8] Common side effects when applied on the skin include acne, skin atrophy, and itchiness.[7] It works by decreasing inflammation.[6]

Mometasone furoate was patented in 1981 and came into medical use in 1987.[10] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide.[11] It is available as a generic medication.[12] A month supply of the inhaler in the United Kingdom costs the NHS about £30 while the nasal spray is less than £2, as of 2019.[12] In 2017, it was the 197th most commonly prescribed medication in the United States, with more than two million prescriptions.[13][14]

References[edit]

  1. ^ "International brands for Mometasone". Drugs.com. Archived from the original on 17 November 2016. Retrieved 17 November 2016.
  2. ^ a b "Mometasone Use During Pregnancy". Drugs.com. 14 February 2020. Archived from the original on 26 October 2020. Retrieved 1 April 2020.
  3. ^ Zia R. Tayab; Tom C. Fardon; Daniel K. C. Lee; Kay Haggart; Lesley C. McFarlane; Brian J. Lipworth; Günther Hochhaus (November 2007). "Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate". Br J Clin Pharmacol. 64 (5): 698–705. doi:10.1111/j.1365-2125.2007.02919.x. PMC 2203259. PMID 17509041. {{cite journal}}: Unknown parameter |last-author-amp= ignored (|name-list-style= suggested) (help)
  4. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 10 July 2021. Retrieved 7 September 2020.
  5. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 10 July 2021. Retrieved 7 September 2020.
  6. ^ a b c d e f g "Mometasone Furoate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 7 October 2016. Retrieved 11 March 2019.
  7. ^ a b c "Mometasone Furoate topical Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 5 August 2020. Retrieved 11 March 2019.
  8. ^ a b c "Mometasone Furoate eent Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 30 April 2016. Retrieved 11 March 2019.
  9. ^ "Mometasone". DrugBank. Archived from the original on 29 June 2019. Retrieved 30 April 2020.
  10. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 488. ISBN 9783527607495. Archived from the original on 2020-02-18. Retrieved 2019-03-01.
  11. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  12. ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 265. ISBN 9780857113382.
  13. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
  14. ^ "Mometasone - Drug Usage Statistics". ClinCalc. Archived from the original on 27 January 2021. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Mometasone&oldid=1219483699"